HomeCompareHZNP vs PEP

HZNP vs PEP: Dividend Comparison 2026

HZNP yields 1.72% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $122.5K in total portfolio value· pulled ahead in Year 2
10 years
HZNP
HZNP
● Live price
1.72%
Share price
$116.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.2K
Annual income
$192.22
Full HZNP calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — HZNP vs PEP

📍 PEP pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHZNPPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HZNP + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HZNP pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HZNP
Annual income on $10K today (after 15% tax)
$146.17/yr
After 10yr DRIP, annual income (after tax)
$163.39/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, PEP beats the other by $53,752.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HZNP + PEP for your $10,000?

HZNP: 50%PEP: 50%
100% PEP50/50100% HZNP
Portfolio after 10yr
$83.4K
Annual income
$31,811.36/yr
Blended yield
38.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

HZNP
Analyst Ratings
15
Buy
10
Hold
Consensus: Buy
Price Target
$127.15
+9.3% upside vs current
Range: $110.00 — $144.00
Altman Z
5.1
Piotroski
8/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HZNP buys
1
PEP buys
0
PoliticianChamberTickerTypeAmountDate
Greg Landsman🏢 House$HZNP▼ Sell$1,001 - $15,0002023-02-03
Daniel Goldman🏢 House$HZNP▼ Sell$15,001 - $50,0002023-01-31
Ro Khanna🏢 House$HZNP▼ Sell$1,001 - $15,0002022-11-03
Ro Khanna🏢 House$HZNP▲ Buy$1,001 - $15,0002022-05-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHZNPPEP
Forward yield1.72%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$22.2K$144.7K
Annual income after 10y$192.22$63,430.49
Total dividends collected$1.8K$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$127.15$172.43

Year-by-year: HZNP vs PEP ($10,000, DRIP)

YearHZNP PortfolioHZNP Income/yrPEP PortfolioPEP Income/yrGap
1$10,872$171.97$10,854$514.44+$18.00HZNP
2← crossover$11,808$174.73$11,982$758.21$174.00PEP
3$12,812$177.36$13,526$1,136.44$714.00PEP
4$13,888$179.85$15,727$1,741.93$1.8KPEP
5$15,043$182.21$19,012$2,750.28$4.0KPEP
6$16,280$184.44$24,173$4,514.44$7.9KPEP
7$17,606$186.55$32,789$7,793.80$15.2KPEP
8$19,027$188.55$48,258$14,354.51$29.2KPEP
9$20,550$190.44$78,586$28,686.63$58.0KPEP
10$22,180$192.22$144,688$63,430.49$122.5KPEP

HZNP vs PEP: Complete Analysis 2026

HZNPStock

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Full HZNP Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this HZNP vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HZNP vs SCHDHZNP vs JEPIHZNP vs OHZNP vs KOHZNP vs MAINHZNP vs MOHZNP vs PMHZNP vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.